Dr. Martens keeps FY27 guidance unchanged after in-line start to trading
Dr. Martens says trading since the start of its financial year is in line with expectations as it heads into its annual general meeting in London. The footwear group keeps its FY27 outlook unchanged and says growth in the U.S. market, especially wholesale, continues to support performance.
Highlights
- Dr. Martens affirmed its FY27 guidance remains unchanged after an in-line start to trading, as announced at its AGM in London today.
- The company reports continued growth in the U.S.—its largest market—with particularly strong results in wholesale and robust performances in Japan and South Korea.
- European markets are performing as expected despite challenging consumer conditions, leading management to maintain its full-year expectations and strategic expansion plans.
FY27 priorities and current trading
As reported by London Stock Exchange, citing the Regulatory News Service, Dr. Martens provides the update alongside its annual general meeting scheduled for 09.30am today at 1-11 Hawley Crescent in Camden, London.The company says it remains focused on its ambition to become the world's most-desired premium footwear brand and is on track with the strategic objectives for FY27 that it set out with its results on 19 May. Those priorities include driving the full-price revenue mix in the UK and DACH, introducing a new sandals range, launching new retail concepts in key cities globally, and unlocking benefits from its operating model and technology.
Regional performance and market backdrop
In regional trading, Dr. Martens says the U.S., its largest market, continues to grow, with wholesale performance described as particularly encouraging. Japan and South Korea, its largest Asian markets, are also performing well.Across Europe, the company says markets are performing as expected despite a challenging consumer backdrop. The update indicates no change to management's wider expectations for the year as the group continues to pursue brand, product and retail expansion goals.
Our earlier coverage of Dr. Martens’ FY27 trading update noted that performance had been in line with expectations since the financial year began in April, prompting the group to keep its fiscal 2027 outlook unchanged. It highlighted encouraging U.S. wholesale demand alongside solid results in Japan and South Korea, while Europe tracked as expected despite a challenging consumer backdrop.
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
